"The Food and Drug Administration (FDA) Center for Biologics Evaluation and ..."

Azadeh Shoaibi et al. (2020)

> Home

Details and statistics

DOI: —

access: closed

type: Conference or Workshop Paper

metadata version: 2024-04-17

- view
  - electronic edition @ amia.org (archived)
- export record
  dblp key:
  - conf/amia/ShoaibiWRMH20
- ask others
- share record
  persistent URL:
  - https://dblp.org/rec/conf/amia/ShoaibiWRMH20
Azadeh Shoaibi, Hui-Lee Wong, Christian Reich, Keran Moll, Tina Hernandez-Boussard:
The Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) Biologics Effectiveness and Safety (BEST) Initiative: How Informatics Can Assist the Secondary Use of Electronic Health Records to Inform Regulatory Decisions. AMIA 2020

a service of

manage site settings

To protect your privacy, all features that rely on external API calls from your browser are turned off by default. You need to opt-in for them to become active. All settings here will be stored as cookies with your web browser. For more information see our F.A.Q.